CD8A and cancer: Type 1 conventional dendritic cells (cDC1, CD11b+ CD11c+ IA-IE+ cells) primarily function to present antigens to CD8+ T cells and initiate a Th1-type immune response, which is associated with favorable cancer prognosis [25,26].